Lymphoblastic Lymphoma study: 4A10
Official title First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.
ClinicalTrials.gov ID: NCT07586618
What this study is testing
What is 4A10?
an investigational monoclonal antibody being studied as a potential treatment for lymphoblastic lymphoma (and related acute lymphoblastic leukemia). is designed to bind CD127 on cancer cells, blocking growth signals and helping the immune system recognize and destroy those cells.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study aims to see if 4A10 is safe, determine the right dose, and observe how the body handles the drug, while also looking for early signs it might work.
- Who it's for
- Adults with relapsed or difficult‑to‑treat acute lymphoblastic leukemia or lymphoblastic lymphoma.
- What's involved
- Participants receive an IV infusion of 4A10 once a week and undergo regular check‑ups and lab tests to monitor side effects and how the drug behaves.
- Time commitment
- The trial lasts up to about 6 treatment cycles (roughly 4‑6 weeks per cycle) with clinic visits each week for the infusion and monitoring.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Confirmed diagnosis of T/B-ALL or T/B-LL
- Relapsed or refractory disease without curative options
- Adequate organ function and performance status Key
You likely can't join if
- Patients with CNS3 disease
- Patients with DNA fragility syndromes (e.g., Fanconi, Bloom), trisomy 21 (Down Syndrome)
- Prior exposure to anti-CD127 therapies
- Uncontrolled infections
The study team makes the final eligibility decision.
Where it is enrolling
- Aurora, Colorado, United States
- Indianapolis, Indiana, United States
- New York, New York, United States
- Fort Worth, Texas, United States
- Houston, Texas, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Aurora, Colorado, United States; Indianapolis, Indiana, United States; New York, New York, United States; Fort Worth, Texas, United States; Houston, Texas, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.